Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCE-MRI Assessment of Bevacizumab and FOLFOX in Metastatic Colorectal Cancer
NCT00602329Phase 2Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Feb 2006
- Primary completion
- Jul 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in colorectal cancer (CRC) (3 arms), sponsored by Abramson Cancer Center. Primary endpoint: Percentage change in tumor blood flow (Ktrans) assessed by DCE-MRI. Started Feb 2006; status: terminated.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00602329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00602329.